Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $153.5 million.

  • 10x Genomics' Total Current Liabilities rose 3045.15% to $153.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $153.5 million, marking a year-over-year increase of 3045.15%. This contributed to the annual value of $153.5 million for FY2025, which is 3045.15% up from last year.
  • 10x Genomics' Total Current Liabilities amounted to $153.5 million in Q4 2025, which was up 3045.15% from $147.3 million recorded in Q3 2025.
  • 10x Genomics' Total Current Liabilities' 5-year high stood at $153.5 million during Q4 2025, with a 5-year trough of $94.4 million in Q1 2022.
  • Its 5-year average for Total Current Liabilities is $116.8 million, with a median of $112.7 million in 2021.
  • Data for 10x Genomics' Total Current Liabilities shows a peak YoY increase of 10408.51% (in 2021) and a maximum YoY decrease of 3104.74% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows 10x Genomics' Total Current Liabilities stood at $110.4 million in 2021, then increased by 18.67% to $131.0 million in 2022, then decreased by 2.9% to $127.2 million in 2023, then dropped by 7.49% to $117.6 million in 2024, then surged by 30.45% to $153.5 million in 2025.
  • Its Total Current Liabilities stands at $153.5 million for Q4 2025, versus $147.3 million for Q3 2025 and $112.2 million for Q2 2025.